This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bridges, E. G.
Right arrow Articles by Luo, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bridges, E. G.
Right arrow Articles by Luo, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2521-2528, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.00029-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B{triangledown}

Edward G. Bridges,{dagger} Jules R. Selden,* and Shouqi Luo

Idenix Pharmaceuticals, Inc., One Kendall Square, Cambridge, Massachusetts 02139

Received 8 January 2008/ Returned for modification 11 February 2008/ Accepted 4 May 2008

Telbivudine is a novel nucleoside drug recently approved for the treatment of patients with chronic hepatitis B. Its nonclinical safety was evaluated in a comprehensive program of studies, including safety pharmacology, acute and chronic toxicity, reproductive and developmental toxicity, genotoxicity, and carcinogenicity. There were no test article-related effects observed in an in vitro hERG assay or in a core battery of safety pharmacology studies (central nervous system, respiratory, and cardiovascular safety pharmacology studies). Telbivudine was well tolerated in rats and in monkeys following single oral doses up to 2,000 mg/kg/day. Except for equivocal axonopathic findings in monkeys and occasional incidences of emesis, soft feces, and minor changes in body weight and food consumption, there was no target organ toxicity observed in mice, rats, or monkeys following oral administration for up to 3, 6, or 9 months, respectively, at doses up to 3,000 mg/kg/day. Axonopathy in the sciatic nerves and in the spinal cords of monkeys dosed at 1,000 mg/kg/day observed in a 9-month study was considered equivocal, as the role of telbivudine in the injury could not be determined. Slightly higher incidences of abortion and premature delivery observed in rabbits dosed at 1,000 mg/kg/day were considered secondary to maternal toxicity. There was no evidence of genotoxicity or carcinogenicity. These results suggest that telbivudine has a favorable safety profile and support its use in patients with chronic compensated hepatitis B viral infection.

* Corresponding author. Mailing address: Idenix Pharmaceuticals, Inc., 60 Hampshire Street, Cambridge, MA 02139. Phone: (617) 995-9800. Fax: (617) 224-4350. E-mail: selden.jules{at}idenix.com

{triangledown} Published ahead of print on 12 May 2008.

{dagger} Present address: West Virginia School of Osteopathic Medicine, 400 North Lee Street, Lewisburg, WV 24901.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2521-2528, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.00029-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»